Can paxlovid cause rebound covid symptoms?

Can Paxlovid cause rebound COVID symptoms?

Paxlovid is an antiviral treatment for COVID-19 that consists of nirmatrelvir and ritonavir. It has been associated with COVID-19 symptom rebound in some patients. Clinical reports describe patients improving during treatment then experiencing a return of symptoms after finishing the five-day course.

How common is rebound after Paxlovid?

Rebound occurs in roughly 2% of patients in clinical trials and may occur higher rates in real-world use. Data from the original trials showed 2.3% of Paxlovid-treated patients developed rebound compared to 1.7% in the placebo group. Real-world studies have reported rates ranging from 2% to 15% depending on the study population.

Does rebound happen only with Paxlovid?

Rebound can occur after any COVID-19 treatment, or even without treatment. Studies show similar rates in patients who did not receive antivirals. The phenomenon appears tied to the virus’s life cycle rather than solely to Paxlovid.

Why does rebound occur after finishing treatment?

Rebound is likely caused by incomplete suppression of the virus. The five-day treatment period may not eliminate all replicating virus in some patients, especially those with weaker immune systems. The virus then resumes activity once drug levels fall.

What happens if I experience rebound after Paxlovid?

Patients experiencing rebound usually have milder symptoms than their initial infection and recover without further treatment. Most cases do not require re-treatment. Some patients may be offered a second five-day course of Paxlovid if they are at high risk.

When does the patent for Paxlovid expire?

Paxlovid is manufactured by Pfizer. The compound patents covering nirmatrelvir and ritonavir are scheduled to expire in 2031. [1]

Who makes generic versions of Paxlovid?

Generic manufacturers have begun filing Abbreviated New Drug Applications (ANDAs) with the FDA. The company that has already received tentative approval for a generic version is Aurobindo Pharma. [2]

How does Paxlovid cost after patent expiry?

Once patents expire in 2031, expected price drops will turn Paxlovid into a low-cost drug similar other generics. Current price estimates for a five-day course of Paxl<|eos|>